Attached files

file filename
EX-99.1 - INVESTOR RELATIONS SLIDE SHOW - AMEDISYS INCdex991.htm
8-K - FORM 8-K - AMEDISYS INCd8k.htm

Exhibit 99.2

AMEDISYS, INC. AND SUBSIDIARIES

RECONCILIATION OF NON-GAAP FINANCIAL MEASURE TO GAAP FINANCIAL STATEMENTS

(Amounts in thousands)

Earnings before interest, taxes, depreciation and amortizaiton (“EBITDA”) and Adjusted EBITDA

 

    For the years ended December 31,   For the three-month periods ended December 31,
    2008   2009   2008   2009

Net income attributable to Amedisys, Inc.

  $ 86,682   $ 135,837   $ 26,341   $ 37,792

Add:

       

Provision for income taxes

    54,743     86,171     15,461     23,397

Interest expense, net

    15,600     11,457     4,931     2,523

Depreciation and amortization

    20,406     28,312     4,678     7,630
                       

EBITDA (1)

  $ 177,431   $ 261,777   $ 51,411   $ 71,342

Add:

       

Certain TLC acquisition costs (2)

    3,991     —       248     —  
                       

Adjusted EBITDA (3)

  $ 181,422   $ 261,777   $ 51,659   $ 71,342
                       

Adjusted Diluted Earnings Per Share Reconciliation

       
     For the years ended December 31,   For the three-month periods ended December 31,
    2008   2009   2008   2009

Diluted earnings per share

  $ 3.22   $ 4.89   $ 0.97   $ 1.35

Add:

       

Certain TLC acquisition costs (2)

    0.09     —       0.01     —  
                       

Adjusted diluted earnings per share (4)

  $ 3.31   $ 4.89   $ 0.98   $ 1.35
                       

 

(1) EBITDA is defined as net income attributable to Amedisys, Inc. before provision for income taxes, net interest expense, and depreciation and amortization. EBITDA should not be considered as an alternative to, or more meaningful than, income before income taxes, cash flow from operating activities, or other traditional indicators of operating performance. This calculation of EBITDA may not be comparable to a similarly titled measure reported by other companies, since not all companies calculate this non-GAAP financial measure in the same manner.

 

(2) Certain TLC integration costs incurred primarily for the payment of severances for TLC employees and for the conversion of the acquired TLC agencies to our operating systems including our Point of Care network. These costs amounted to $0.2 million ($0.1 million, net of income tax) or $0.01 per diluted share and $4.0 million ($2.4 million, net of income tax) or $0.09 per diluted share for the three-month period ended December 31, 2008 and the twelve-month period ended December 31, 2008, respectively.

 

(3) Adjusted EBITDA is defined as net income attributable to Amedisys, Inc. before provision for income taxes, net interest expense, and depreciation and amortization plus certain TLC integration costs. Adjusted EBITDA should not be considered as an alternative to, or more meaningful than, income before income taxes, cash flow from operating activities, or other traditional indicators of operating performance. This calculation of adjusted EBITDA may not be comparable to a similarly titled measure reported by other companies, since not all companies calculate this non-GAAP financial measure in the same manner.

 

(4) Adjusted diluted earnings per share is defined as diluted earnings per share plus the earnings per share effect of certain TLC acquisition costs. Adjusted diluted earnings per share should not be considered as an alternative to, or more meaningful than, income before income taxes, cash flow from operating activities, or other traditional indicators of operating performance. This calculation of adjusted diluted earnings per share may not be comparable to a similarly titled measure reported by other companies, since not all companies calculate this non-GAAP financial measure in the same manner.